BWFA
PDLI

Baltimore-Washington Financial Advisors’s PDL BioPharma, Inc. PDLI Stock Holding History

Baltimore-Washington Financial Advisors’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-62
Closed -$1K – 336
2013
Q4 		$1K Buy
+62
New +$522 ﹤0.01% 303

Other funds holding PDLI

Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
AAM
Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Baltimore-Washington Financial Advisors's PDLI Position: Q1 2014 in Review

Baltimore-Washington Financial Advisors sold out of PDL BioPharma, Inc. (PDLI) in Q1 2014, closing a stake of 62 shares — an estimated $1K sold.

Baltimore-Washington Financial Advisors first reported a position in PDLI in Q4 2013 and held it in 1 quarter. The position peaked at $1K in Q4 2013. 233 funds tracked by Wall St. Rank hold PDLI as of Q1 2014.

  • Baltimore-Washington Financial Advisors reported no remaining PDL BioPharma, Inc. position as of Q1 2014 after selling out during the quarter.
  • Baltimore-Washington Financial Advisors sold 62 PDL BioPharma, Inc. shares in Q1 2014, an estimated $1K.
  • Baltimore-Washington Financial Advisors first reported a position in PDL BioPharma, Inc. in Q4 2013 and held it in 1 quarter.
  • Baltimore-Washington Financial Advisors's PDL BioPharma, Inc. position peaked at $1K in Q4 2013.
  • 233 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q1 2014.

Based on Baltimore-Washington Financial Advisors's 13F filing for Q1 2014, filed 28 Apr 2014.